TY  - JOUR
A1  - Welzel, Tania Mara
A1  - Dultz, Georg
A1  - Zeuzem, Stefan
T1  - Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors
T2  - International journal of cardiology. Heart & vasculature
N2  - The establishment of robust HCV cell culture systems and characterization of the viral life cycle provided the molecular basis for highly innovative, successful years in HCV drug development. With the identification of direct-acting antiviral agents (DAAs), such as NS3/4A protease inhibitors, NS5A replication complex inhibitors, nucleotide and non-nucleoside polymerase inhibitors, as well as host cell targeting agents, novel therapeutic strategies were established and competitively entered clinical testing. The first-in-class NS3/4A protease inhibitors telaprevir and boceprevir, approved in 2011, were recently outpaced by the pan-genotypic nucleotide polymerase inhibitor sofosbuvir that in combination with pegylated interferon and ribavirin, further shortens therapy durations and also offers the first interferon-free HCV treatment option. In the challenging race towards the goal of interferon-free HCV therapies, however, several oral DAA regimens without nucleotide polymerase inhibitors that combine a NS3/4A protease inhibitor, a NS5A inhibitor and/or a non-nucleoside polymerase inhibitor yielded competitive results. Second generation NS3/4A protease and NS5A inhibitors promise an improved genotypic coverage and a high resistance barrier. Results of novel DAA combination therapies without the backbone of a nucleotide polymerase inhibitor, as well as treatment strategies involving host targeting agents are reviewed herein.
KW  - All oral
KW  - Direct-acting antiviral agents (DAAs)
KW  - Host-targeting agents (HTAs)
KW  - Interferon-free HCV treatment
KW  - NS3/4A protease inhibitors (PI)
KW  - NS5A inhibitors
KW  - Non-nucleoside polymerase inhibitors (NNI)
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/49954
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-499548
SN  - 2352-9067
N1  - Open access under CC BY-NC-ND license.
VL  - 61
IS  - 1, Supplement
SP  - S98
EP  - S107
PB  - Elsevier
CY  - Amsterdam [u. a.]
ER  -